A H Gifford1, A B Nymon, A Ashare. 1. Pulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire; Dartmouth Lung Biology Center, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Abstract
INTRODUCTION: Cystic fibrosis (CF) is characterized by low circulating levels of insulin-like growth factor-1 (IGF-1), a hormone produced by the liver that governs anabolism and influences immune cell function. Because treatment of CF pulmonary exacerbation (CFPE) often improves body weight and lung function, we questioned whether serum IGF-1 trends were emblematic of these responses. Initially, we compared serum levels between healthy adults with CF and controls of similar age. We then measured serum IGF-1 throughout the CFPE cycle. We also investigated correlations among IGF-1 and other serum biomarkers during CFPE. METHODS: Anthopometric, spirometric, and demographic data were collected. Serum IGF-1 concentrations were measured by ELISA. RESULTS: CF subjects in their usual state of health had lower serum IGF-1 levels than controls. Serum IGF-1 concentrations fell significantly from baseline at the beginning of CFPE. Treatment with intravenous antibiotics was associated with significant improvement in serum IGF-1 levels, body mass index (BMI), and percent-predicted forced expiratory volume in 1 sec (FEV1 %). At early and late CFPE, serum IGF-1 was directly correlated with FEV1 %, serum iron, hemoglobin concentration, and transferrin saturation (TSAT) and indirectly correlated with alpha-1-antitrypsin. CONCLUSIONS: This study not only supports the paradigm that CF is characterized by IGF-1 deficiency but also that trends in lung function, nutritional status, and serum IGF-1 are related. Improvements in all three parameters after antibiotics for CFPE likely highlight the connection between lung function and nutritional status in CF. Close correlations among IGF-1 and iron-related hematologic parameters suggest that IGF-1 may participate in CF iron homeostasis, another process that is known to be influenced by CFPE.
INTRODUCTION:Cystic fibrosis (CF) is characterized by low circulating levels of insulin-like growth factor-1 (IGF-1), a hormone produced by the liver that governs anabolism and influences immune cell function. Because treatment of CF pulmonary exacerbation (CFPE) often improves body weight and lung function, we questioned whether serum IGF-1 trends were emblematic of these responses. Initially, we compared serum levels between healthy adults with CF and controls of similar age. We then measured serum IGF-1 throughout the CFPE cycle. We also investigated correlations among IGF-1 and other serum biomarkers during CFPE. METHODS: Anthopometric, spirometric, and demographic data were collected. Serum IGF-1 concentrations were measured by ELISA. RESULTS: CF subjects in their usual state of health had lower serum IGF-1 levels than controls. Serum IGF-1 concentrations fell significantly from baseline at the beginning of CFPE. Treatment with intravenous antibiotics was associated with significant improvement in serum IGF-1 levels, body mass index (BMI), and percent-predicted forced expiratory volume in 1 sec (FEV1 %). At early and late CFPE, serum IGF-1 was directly correlated with FEV1 %, serum iron, hemoglobin concentration, and transferrin saturation (TSAT) and indirectly correlated with alpha-1-antitrypsin. CONCLUSIONS: This study not only supports the paradigm that CF is characterized by IGF-1 deficiency but also that trends in lung function, nutritional status, and serum IGF-1 are related. Improvements in all three parameters after antibiotics for CFPE likely highlight the connection between lung function and nutritional status in CF. Close correlations among IGF-1 and iron-related hematologic parameters suggest that IGF-1 may participate in CF iron homeostasis, another process that is known to be influenced by CFPE.
Authors: Elena Succurro; Franco Arturi; Vittoria Caruso; Stefania Rudi; Angela Sciacqua; Francesco Andreozzi; Marta L Hribal; Francesco Perticone; Giorgio Sesti Journal: Thromb Haemost Date: 2010-11-05 Impact factor: 5.249
Authors: Mark P Rogan; Leah R Reznikov; Alejandro A Pezzulo; Nicholas D Gansemer; Melissa Samuel; Randall S Prather; Joseph Zabner; Douglas C Fredericks; Paul B McCray; Michael J Welsh; David A Stoltz Journal: Proc Natl Acad Sci U S A Date: 2010-11-08 Impact factor: 11.205
Authors: Emer P Reeves; David A Bergin; Sean Fitzgerald; Elaine Hayes; Joanne Keenan; Michael Henry; Paula Meleady; Isabel Vega-Carrascal; Michelle A Murray; Teck Boon Low; Cormac McCarthy; Emmet O'Brien; Martin Clynes; Cedric Gunaratnam; Noel G McElvaney Journal: J Cyst Fibros Date: 2011-10-28 Impact factor: 5.482
Authors: J C Bucuvalas; S D Chernausek; M P Alfaro; S K Krug; W Ritschel; R W Wilmott Journal: J Pediatr Gastroenterol Nutr Date: 2001-11 Impact factor: 2.839
Authors: Alex H Gifford; Lisa A Moulton; Dana B Dorman; Gordana Olbina; Mark Westerman; H Worth Parker; Bruce A Stanton; George A O'Toole Journal: Clin Transl Sci Date: 2012-06-01 Impact factor: 4.689
Authors: Sara Pagani; Elena Bozzola; Gloria Acquafredda; Vito Terlizzi; Valeria Raia; Fabio Majo; Alberto Villani; Mauro Bozzola Journal: Clin Med Res Date: 2019-08-28
Authors: Daniel H Leung; Sonya L Heltshe; Drucy Borowitz; Daniel Gelfond; Margaret Kloster; James E Heubi; Michael Stalvey; Bonnie W Ramsey Journal: JAMA Pediatr Date: 2017-06-01 Impact factor: 16.193
Authors: Margaret P Marks; Sonya L Heltshe; Arthur Baines; Bonnie W Ramsey; Lucas R Hoffman; Michael S Stalvey Journal: Nutrients Date: 2021-12-10 Impact factor: 5.717